Table I.
Stage I NSCLC patient characteristics relative to GADD153 expression.
| GADD153 expression in tumor tissues | |||
|---|---|---|---|
|
|
|||
| Patient characteristics | Positive (n=29) | Negative (n=47) | P-value |
| Gender | |||
| Male | 18 | 38 | 0.07 |
| Female | 11 | 9 | |
| Smoking status | |||
| Smoker; packs/year, mean ± SD | 21; 45.0±28.73 | 33; 35.2±19.69 | 0.112; 0.311 |
| Non-smoker | 6 | 4 | |
| Unknown | 2 | 10 | |
| Pathology | 0.674 | ||
| Adenocarcinoma | 16 | 21 | |
| Squamous cell carcinoma | 12 | 24 | |
| Other | 1 | 2 | |
| Histological grade | 0.305 | ||
| Well-differentiated | 12 | 10 | |
| Moderately differentiated | 7 | 17 | |
| Poorly differentiated | 6 | 12 | |
| Unclassified | 4 | 8 | 0.735 |
| TNM stage | |||
| T1N0M0 | 7 | 13 | |
| T2N0M0 | 22 | 34 | |
| Distant metastasis | 0 | 8 | 0.029 |
| Mean survival time (months, 95% CI) | |||
| Disease-free | 54.19 (50.736–57.652) | 46.97 (38.062–55.881) | 0.084 |
| Disease-specific | 53.85 (50.702–57.002) | 28.80 (13.895–43.705) | 0.020 |
| Overall | 52.18 (46.735–57.624) | 53.29 (49.123–57.447) | 0.743 |
GADD153, growth arrest and DNA damage-inducible gene 153; NSCLC, non-small cell lung cancer; CI, confidence interval.